Current Issue

Clinical/translational cancer immunotherapy

• Original research: Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials (25 May, 2022)

  Espen Basmo Ellingsen, Elin Aamdal, Tormod Guren, Wolfgang Lilleby, Paal F Brunsvig, Sara M Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg
• Original research: Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma (23 May, 2022)

  Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, Rohini Narayanaswamy, Sebastien Ronseaux, Christine Hudson, Adriana E Tron, Marc L Hyer, Megan Montoya, Abigail L Mende, Takahide Nejo, Kira M Downey, David Diebold, Min Lu, Brandon Nicolay, Hideho Okada
• Original research: Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial (20 May, 2022)

  Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong, Dipti Jain, Dilichukwu O Chudy Onwugaje, Abdulrahman Abonofal, Anneleis F Willett, Michael Overman, Brandon Smaglo, Ryan W Huey, Funda Meric-Bernstam, Gauri R Varadhachary, Aung Naing
• Original research: Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies (20 May, 2022)

  Mathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, Sophie Cousin, Maxime Brunet, Sylvestre Le Moulec, François Le Loarer, Christophe Rey, Jean-Charles Soria, Fabrice Barlesi, Alban Bessede, Jean-Yves Scoazec, Isabelle Soubeyran, Antoine Italiano
• Original research: Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial (18 May, 2022)

  Jessica Hochberg, Jaclyn Basso, Qiuhu Shi, Liana Klejmont, Allyson Flower, Kristina Bortfeld, Lauren Harrison, Carmella van de Ven, Chitti Moorthy, Humayun Islam, Perry Gerard, Stephan Voss, Mitchell S Cairo
• Original research:

  A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

  (17 May, 2022)

  Apple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Björn Önfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M Brea, Maria I Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
• Original research: Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma (17 May, 2022)

  Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
• Original research:

  CD4⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

  (17 May, 2022)

  Minglu Xiao, Luoyingzi Xie, Guoshuai Cao, Shun Lei, Pengcheng Wang, Zhengping Wei, Yuan Luo, Jingyi Fang, Xingxing Yang, Qizhao Huang, Lifan Xu, Junyi Guo, Shuqiong Wen, Zhiming Wang, Qing Wu, Jianfang Tang, Lisha Wang, Xiangyu Chen, Cheng Chen, Yanyan Zhang, Wei Yao, Jianqiang Ye, Ran He, Jun Huang, Lilin Ye
• Original research: Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial (17 May, 2022)

  Federica Riccardo, Lidia Tarone, Mariateresa Camerino, Davide Giacobino, Selina Iussich, Giuseppina Barutello, Maddalena Arigoni, Laura Conti, Elisabetta Bolli, Elena Quaglino, Irene Fiore Merighi, Emanuela Morello, Alfredo Dentini, Soldano Ferrone, Paolo Buracco, Federica Cavallo
• Original research: Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade (16 May, 2022)

  Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle
• Original research: Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma (11 May, 2022)

  Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
• Original research: Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study (10 May, 2022)

  Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Qing Zou, Nianzeng Xing, Hong Luo, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Chunxia Chen, Quanren Wang, Ding-Wei Ye
• Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation (9 May, 2022)

  Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Constance M Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Crystal Mackall, Terry J Fry, Sandhya Panch, Steven Highfill, David Stroncek, Lauren Little, Daniel W Lee, Haneen Shalabi, Bonnie Yates, Nirali Shah